Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wrapp

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Nature Communications|November 30, 2023
Engineered immunogens to elicit antibodies against conserved coronavirus epitopesA Brenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike proteinAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus EpitopesBrenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
Science (New York, N.Y.)|June 17, 2020
Broad neutralization of SARS-related viruses by human monoclonal antibodiesAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Immunity|April 6, 2021
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesMaryam Mukhamedova, Daniel Wrapp, Chen-Hsiang Shen, et al.
Mbio|January 11, 2023
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing AntibodiesFrederic Bibollet-Ruche, Ronnie M Russell, Wenge Ding, et al.
Nature Communications|May 21, 2020
Immunogenicity of a DNA vaccine candidate for COVID-19Trevor R F Smith, Ami Patel, Stephanie Ramos, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessKizzmekia S Corbett, Darin Edwards, Sarah R Leist, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Nature Communications|November 30, 2023
Engineered immunogens to elicit antibodies against conserved coronavirus epitopesA Brenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike proteinAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus EpitopesBrenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
Science (New York, N.Y.)|June 17, 2020
Broad neutralization of SARS-related viruses by human monoclonal antibodiesAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Immunity|April 6, 2021
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesMaryam Mukhamedova, Daniel Wrapp, Chen-Hsiang Shen, et al.
Mbio|January 11, 2023
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing AntibodiesFrederic Bibollet-Ruche, Ronnie M Russell, Wenge Ding, et al.
Nature Communications|May 21, 2020
Immunogenicity of a DNA vaccine candidate for COVID-19Trevor R F Smith, Ami Patel, Stephanie Ramos, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessKizzmekia S Corbett, Darin Edwards, Sarah R Leist, et al.
Pageof 7